摘要
目的:研究中药复方制剂肺瘤平Ⅱ号对Lewis肺癌小鼠移植瘤组织基质金属蛋白酶-9(MMP-9)及金属蛋白酶组织抑制因子-1(TIMP-1)表达的影响,从分子水平探讨了肺瘤平Ⅱ号抗肿瘤的作用机制。方法:60只C57BL/6近交系小鼠右腋皮下接Lewis瘤细胞悬液0.2 mL,随机分为模型组、环磷酰胺(CTX,60 mg.kg-1,ip,qd)组、榄香烯组(65 mg.kg-1,ip,qd)、参一胶囊组(5 mg.kg-1,ig,qd)、肺瘤平Ⅱ号高、低剂量组(10,25 g.kg-1,ig,qd),每组10只。实验d2开始给药,除CTX组给药1 d外,其余各组均给药12 d。实验d14以RT-PCR方法测荷瘤组织MMP-9及TIMP-1的表达。结果:与模型组比较,肺瘤平Ⅱ号、参一胶囊及榄香烯注射液均可降低荷瘤组织MMP-9的含量,提高TIMP-1的含量,肺瘤平Ⅱ号高剂量组作用更为显著,CTX调节MMP-9及TIMP-1作用不明显。结论:中药复方制剂肺瘤平Ⅱ号通过调节肿瘤细胞MMP-9和TIMP-1的表达,发挥抗肿瘤作用。
Objective： To study effects and mechanism of an herbal compound Feiliuping Ⅱ on the mRNA expression of matrix metalloproteinase-9 （MMP-9） and tissue inhibitor of metalloproteinase-1 （TIMP-1） in Lewis lung cancer cells of mice. Methods： Sixty C57BL/6 mice were subcutaneously injected at right armpit with Lewis oncocyte suspension fluids 0.2 mL, and subsequently randomly 1 ： 1 assigned to model group （blank control）, CTX group （60 mg· kg^-1 , ip）, Shenyi capsule group （5 mg· kg^-1 , ig, qd）, Elemene injection group（65 mg· kg^-1, ip, qd）, or two Feiliuping Ⅱ groups （ 10 or 25 mg· kg^-1, ig, qd）. The study drugs were administered for 12 days but the CTX that was injected for one day only. The MMP-9 and TIMP-1 concentrations in tumor cells were measured using RT-PCR on the 14th day of the treatment. Results： Compared to the model group, Feiliuping Ⅱ, Shenyi and Elemene decreased MMP-9 concentration but increased TIMP-1 concentration （ P 〈 0.05 or P 〈 0.01）. Feiliuping Ⅱ 25 mg· kg^-1 showed the most significant effects on the mRNA expression of MMP-9 and TIMP-1 compared to the rest of groups （P 〈 0.01 ）. The CTX had no significant modulation of the MMP-9 and TIMP-1. Conclusion： Feiliuping Ⅱ acts anti-tumor activities by modulating MMP-9 and TIMP-1 expression.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2005年第10期1162-1165,共4页
Chinese Journal of New Drugs
